Accessibility Menu
BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

(NASDAQ) BMRN

Current Price$59.14
Market Cap$11.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)+354%
5 Year-26%
1 Year+3%
1 Month+8%
BioMarin Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 59.112026-07-20
BioMarin Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.15%USD 59.202026-07-13
1 month+8.08%USD 54.692026-06-18
3 month+8.22%USD 54.622026-04-21
Year to date-0.54%USD 59.432025-12-31
1 year+3.18%USD 57.292025-07-18
3 year-32.62%USD 87.722023-07-21
5 year-25.79%USD 79.652021-07-21
Since inception+354.02%USD 13.131999-07-23

BioMarin Pharmaceutical Financials at a Glance

Market Cap

$11.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.24B

Net Income (TTM)

$268.74M

EPS (TTM)

$1.37

P/E Ratio

43.48

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$59.14

Volume

1,177,854.393

Open

$59.59

Previous Close

$59.11

Daily Range

$59.00 - $59.94

52-Week Range

$49.26 - $66.28

Estimated Earnings Date

Aug 3, 2026

BMRN News

DNA on monitor, scientists

Should You Buy BioMarin Pharmaceutical Before Feb. 18?

Keith SpeightsJan 31, 2026
Two people participating in a telehealth session

Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday

Eric VolkmanOct 28, 2025
Foolcom-Featured.png

BioMarin (BMRN) Q2 Revenue Jumps 16%

Motley Fool Markets TeamAug 4, 2025
Person checking medicine on a shelf in a pharmacy

Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today

Eric VolkmanFeb 20, 2025
DNA genetic sequencing biotech-1200x675-128554e.jpg

BioMarin: EPS Surges Past Expectations

Motley Fool Markets TeamFeb 19, 2025
GettyImages-2152342460-600x400-bf06395.jpg

BioMarin Reports 28% Jump in Revenue

Motley Fool Markets TeamOct 29, 2024
DNA genetic sequencing biotech.jpg

BioMarin: Q2 Revenue Soars 20%

Motley Fool Markets TeamAug 5, 2024
scientist looking through microscope (1)

Why BioMarin Pharmaceuticals Fell 6.9% on Thursday

James HalleyOct 27, 2022
Page 1

BMRN: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioMarin Pharmaceutical

BioMarin makes medicines for people with rare genetic conditions that can be life-threatening. These therapies replace missing enzymes or fix growth signals to help patients live better lives. The company delivers these specialized treatments to hospitals and pharmacies in many countries.

What is in the Medicine Cabinet?

  • Skeletal Conditions: VOXZOGO is a daily injection for children with achondroplasia, a form of short stature; it earned $927 million in 2025 net product revenue.
  • Enzyme Replacement Therapies: VIMIZIM and NAGLAZYME treat metabolic disorders called MPS; VIMIZIM generated $792 million and NAGLAZYME earned $485 million in 2025.
  • Metabolic Health: PALYNZIQ and KUVAN treat phenylketonuria (PKU), a condition where the body cannot break down a specific amino acid; PALYNZIQ earned $433 million in 2025.
  • Batten Disease Treatment: BRINEURA is a specialized therapy for children with a progressive brain disorder; it generated $186 million in 2025 net product revenue.

New Deals and Direction

  • Purchased Inozyme Pharma, Inc. in July 2025 to add a late-stage enzyme therapy for bone and vessel diseases to its portfolio.
  • Reached an agreement in December 2025 to buy Amicus Therapeutics, Inc. for $4.8 billion to gain new therapies for Fabry and Pompe diseases.
  • Committed to a plan in December 2025 to stop selling its gene therapy, ROCTAVIAN, due to lower than expected sales.

What Makes BioMarin Different

The company maintains its own manufacturing plants in California and Ireland to control the quality of complex biologic drugs. It focuses on very small patient groups who have no other treatment options, allowing for specialized pricing and high market share.

The Recent Financial Record

  • Total revenues rose to $3.2 billion for the full year 2025, supported by the expansion of VOXZOGO.
  • Revenue reached $875 million in Q4 2025, representing a 17% increase from the $747 million reported in Q4 2024.
  • Operating income fell 51% to $79 million in Q4 2025 compared to $161 million in Q4 2024.
  • Free cash flow was $59 million in Q4 2025, down 64% from $165 million in the same period for 2024.
  • The company reported a net loss of $47 million in Q4 2025, down 137% from a net income of $125 million in Q4 2024.

Bottom Line

BioMarin has shifted from a research-focused firm to a global commercial business with eight approved therapies. Its current strategy emphasizes large acquisitions and a focus on skeletal and enzyme treatments to drive future growth.

AI Generated • Apr 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,221

CEO

Alexander Hardy

Website

www.biomarin.com

Headquarters

San Rafael, CA 94901, US

BMRN Financials

Key Financial Metrics (TTM)

Gross Margin

75.93%

Operating Margin

13.55%

Net Income Margin

8.29%

Return on Equity

4.41%

Return on Capital

7.93%

Return on Assets

3.13%

Earnings Yield

2.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

193.28M

Volume

1.18M

Avg. Volume

2.04M

Financials (TTM)

Gross Profit

$2.46B

Operating Income

$439.21M

EBITDA

$482.49M

Operating Cash Flow

$874.25M

Capital Expenditure

-$107.19M

Free Cash Flow

$767.06M

Cash & ST Invst.

$2.22B

Total Debt

$1.44B

BioMarin Pharmaceutical Performance Analysis

BioMarin Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,047,498,00010.9%
20232023-12-31USD 2,419,412,00018.2%
20242024-12-31USD 2,839,207,00017.4%
20252025-12-31USD 3,241,864,00014.2%
BioMarin Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.8%
Q32025-09-30-6.0%
Q42025-12-3112.7%
Q12026-03-31-12.4%
BioMarin Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.75N/A
20232023-12-31USD 0.8816.8%
20242024-12-31USD 2.21152.3%
20252025-12-31USD 1.80-18.2%
BioMarin Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3029.5%
Q32025-09-30-113.0%
Q42025-12-31-37.5%
Q12026-03-31345.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$766.21M

+2.8%

Gross Profit

$571.21M

-3.8%

Gross Margin

74.55%

N/A

Market Cap

$11.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.58M

N/A

Employees

3,221

N/A

Net Income

$105.53M

-43.2%

EBITDA

$172.57M

-34.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.22B

+74.7%

Total Debt

$1.44B

+139.2%

Accounts Receivable

$903.91M

+22.3%

Inventory

$1.27B

-0.1%

Long Term Debt

$1.43B

+140.1%

Short Term Debt

$9.32M

+47.7%

Return on Assets

3.13%

N/A

Return on Invested Capital

5.63%

N/A

Free Cash Flow

$199.73M

+26.7%

Operating Cash Flow

$220.65M

+26.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TECHBio-Techne Corporation
$71.64-0.67%
MDGLMadrigal Pharmaceuticals, Inc.
$535.69-3.21%
ALGNAlign Technology, Inc.
$175.05-0.97%
HALOHalozyme Therapeutics, Inc.
$77.09-0.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
PATHUiPath
$12.16+0.00%
ZYBTZhengye Biotechnology
$8.01+10.48%
AALAmerican Airlines Group
$15.14+0.01%
ACHRArcher Aviation
$5.31+0.20%

Questions About BMRN

What is the current price of BioMarin Pharmaceutical?

BioMarin Pharmaceutical is trading at $59.11 per share.

What is the 52-week range for BioMarin Pharmaceutical?

Over the past 52 weeks, BioMarin Pharmaceutical has traded between $49.26 and $66.28.

How much debt does BioMarin Pharmaceutical have?

As of the most recent reporting period, BioMarin Pharmaceutical reported total debt of $1.45B.

How much cash does BioMarin Pharmaceutical have on hand?

BioMarin Pharmaceutical reported $2.22B in cash and cash equivalents in its most recent financial results.

What is BioMarin Pharmaceutical’s dividend yield?

BioMarin Pharmaceutical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services